Overview of Pectox lisina

Quick Facts

Property	Description
Active ingredient	Carbocysteine (as L-Lysine salt)
Form	Oral solution or syrup
Pharmacological class	Mucolytic agent (Secretolytic)
General Purpose	Modifies mucus viscosity for easier clearance
Origin	Synthetic derivative of L-cysteine

What Type of Medicine is Pectox lisina?

Pectox lisina is a pharmaceutical preparation fundamentally defined as a mucolytic agent, belonging to the broader category of secretolytic drugs. Its primary function is defined by its active ingredient, Carbocysteine, which operates as a rheological modifier of respiratory secretions. The drug is used for reducing the viscosity, or thickness, of mucus, making it easier to expel. Carbocysteine is utilized to modify sputum viscosity, which assists by making the accumulated secretions easier to bring up.

The active substance, Carbocysteine, is a synthetic derivative of the natural amino acid L-cysteine, positioning it within the established group of compounds that chemically modify and thin airway mucus. Pectox lisina is specifically formulated using the highly soluble L-Lysine salt (Carbocysteine Lysine), a feature that helps optimize its stability as a liquid for oral consumption.

Composition and Pharmaceutical Form

The core active component is Carbocysteine, compounded with L-Lysine to create a highly soluble salt form, often referred to as Carbocysteine Lysine. This salt format enhances its incorporation and stability within an aqueous vehicle base. The usual dosage form is a convenient liquid formulation, such as an oral solution or a syrup, which is intended for administration via the oral route (peroral). This form is often preferred for patient groups, such as those with difficulty swallowing tablets, facilitating systemic absorption to allow the active agent to reach the respiratory tract.

General Purpose and Action

The general purpose of Pectox lisina is intrinsically linked to its mucolytic classification: it addresses the challenges associated with overly thick, retained secretions in the respiratory tract. By acting to chemically disrupt the structure of the mucoproteins, the drug reduces the viscosity of the mucus, thereby thinning it. This change in consistency enhances the body's natural mechanisms for clearance, such as coughing and ciliary movement, ultimately providing a means to manage the discomfort caused by the retention of tenacious airway material and facilitating easier breathing. Carbocysteine is utilized as a treatment for reducing the adherence of sputum, helping to make sticky mucus less likely to cling to the airway walls.

Regulatory References

What side effects are possible with Pectox lisina?

Possible side effects and safety information

Regulatory documents classify the possible adverse effects of Carbocysteine Lysine by frequency and the body system affected. The most frequently documented adverse reactions primarily involve the Gastrointestinal disorders system, where effects such as nausea and diarrhoea are officially classified as common in regulatory labels. Vomiting is typically classified as uncommon.

Less frequently, adverse reactions may affect the Skin and subcutaneous tissue and the Immune system disorders.

Serious Adverse Reactions and Safety Constraints

The regulatory safety profile explicitly notes the potential for rare but clinically significant adverse reactions, which include systemic responses such as Anaphylactic reactions (severe allergic response) and severe cutaneous reactions, including Fixed drug eruption and isolated reports of Bullous Dermatitis. The documentation also notes that gastrointestinal bleeding is a reported, potentially serious effect.

Official labeling imposes specific constraints on the use of this medicine. It is contraindicated in individuals with a known hypersensitivity to the active substance or any related components. Furthermore, the medicine is officially restricted for individuals with active peptic ulceration (stomach or duodenal ulcer) due to the reported risk of gastrointestinal complications. Caution is also generally recommended for use in the elderly population and is restricted in the very young paediatric population, consistent with regulatory safety protocols.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents for Carbocysteine (Pectox lisina) describe a specific profile for overdosage, focusing on the documentation of clinical manifestations and the requirement for immediate medical attention under defined circumstances.

Feature	Documented Regulatory Statement
Documented Presentations	Primarily gastrointestinal disturbance. Specific symptoms include gastralgia (stomach pains), nausea, vomiting, diarrhea, and abdominal pain.
Urgent Help Required	You must contact the nearest hospital or doctor immediately if the amount ingested exceeds 4 to 5 times the recommended dose.

Management Factor	Official Regulatory Guidance
Antidote Information	No specific antidote is known for the active substance.
Management Measures	Management involves the institution of symptomatic treatment or supportive therapy. Procedural steps such as gastric lavage may be considered, followed by necessary observation.

The regulatory profile explicitly identifies the Gastrointestinal system as the most clearly affected system in overdose reports. The guidance on emergency action is specific, mandating that the immediate seeking of medical help is required when the dose surpasses a clearly defined threshold. The official documentation confirms the absence of a specific antidote, which necessitates a clinical management approach centered entirely on symptomatic treatment and observation, as documented in the prescribing information authorized by government health authorities.

Therapeutic Uses of Pectox lisina

What Pectox lisina Treats: Main Uses and Benefits

Pectox lisina (Carbocysteine Lysine) is generally used in clinical contexts where thick, retained airway secretions cause symptoms that interfere with daily functioning. Its therapeutic use is focused on managing symptoms that create noticeable physiological strain and helping to ease the overall symptom load. It is categorized as a mucolytic agent for the adjunctive therapy of respiratory tract disorders.

The medication is commonly used across conditions presenting with acute episodes and chronic conditions characterized by periods of heightened symptoms. This includes Chronic Obstructive Pulmonary Disease (COPD), Chronic Bronchitis, and acute bronchitis where the cough is unproductive due to tenacious mucus. It may also be applied in therapeutic domains where symptoms are related to localized physical discomfort from thick secretions, such as certain otorhinolaryngological (ENT) manifestations.

The primary focus is symptomatic relief: the medication supports the patient during difficult episodes by easing distress and may help maintain a sense of stability when symptoms are more noticeable. The intent is to assist with easing symptomatic strain related to difficult expectoration.

“The medication may contribute to easing the overall symptom load during periods of heightened symptoms, which supports more comfortable symptom management.”

Quick Fact: Relief for Difficult Expectoration	Focus	Symptom Category
Primary Target	Viscous, retained airway mucus	May assist with easing the effort related to clearing the airways
Chronic Use	COPD, Chronic Bronchitis	May support managing the overall symptom load
Acute Use	Acute Bronchitis, Respiratory Episodes	Is applied when supportive relief is appropriate during acute phases

Eligibility and Restrictions for Use

Eligibility and Contraindications

Pectox lisina, which contains the active substance carbocisteine lysine, is approved for use in adults, adolescents older than 12 years, and children older than 2 years of age. Official regulatory information strictly defines which groups must not take this medicine.

Contraindicated Populations

Use of Pectox lisina is contraindicated and must be avoided for several specific conditions and populations:

Individuals with a known hypersensitivity or allergy to carbocisteine lysine or any of the product's excipients.
Patients with an active gastroduodenal ulcer.
Children under 2 years of age are prohibited from using this medicine for safety reasons.

Use Restrictions and Special Considerations

Certain physiological states and conditions require special attention:

Pregnancy: Use is preferably avoided as a precautionary measure.
Lactation (Breastfeeding): Use is not recommended due to a lack of sufficient data on its use in breastfeeding women.
Phenylketonuria (PKU): The oral solution contains aspartame (a source of phenylalanine), requiring caution in individuals with this metabolic condition.

What should I know about interactions with other medicines?

Pharmacodynamic Interaction Restrictions

Official regulatory labels establish pharmacodynamic constraints by defining certain medicinal product combinations as not recommended due to a functional interference with the drug’s mucolytic action. This classification is primarily based on the risk of causing the retention of bronchial secretions.

Product Category
Antitussives (Cough Suppressants)
Substances that dry secretions (e.g., Atropinic Agents)

Co-administration with antitussives is not recommended because the clearance of thinned mucus requires an intact cough reflex, which these medicines suppress. Similarly, co-administration with substances that dry secretions is not recommended as this antagonizes the necessary fluidifying effect of the mucolytic agent.

Other Interaction Considerations

Metabolic and Pharmacokinetic Profile: Official regulatory sources do not document formal pharmacokinetic interactions, such as those related to Cytochrome P450 enzymes or drug transporters, that would significantly alter the exposure or clearance of Carbocysteine or other co-administered medicinal products.

Population-Specific Caution: Caution is specifically advised when Pectox lisina is co-administered with medications known to cause gastrointestinal bleeding (including Non-Steroidal Anti-Inflammatory Drugs or corticosteroids) in patients who have a pre-existing history of gastroduodenal ulcers. This restriction is related to the potential for an additive risk of gastrointestinal bleeding in this susceptible population.

Food, Alcohol, and Timing: No mandatory timing requirements for dose separation are documented in official regulatory labels, nor are there formal restrictions concerning interactions with food, alcohol, or herbal products.

Mechanism of Action

Pectox lisina is a lysine salt of carbocisteine, which is the active component providing the primary pharmacodynamic action. The drug targets the epithelial cells of the respiratory tract, where its S-carboxymethylcysteine moiety is recognized. Carbocisteine functions as a mucoregulator primarily by modulating intracellular glycosyltransferase enzymes. Specifically, it is proposed to modify the biosynthesis of acidic and neutral glycoproteins within goblet cells and submucosal glands, altering their relative proportions. This downstream effect on mucin protein structure and quantity leads to a reduction in the abnormal viscosity of the mucus layer.

Simultaneously, the metabolite cysteine from the carbocisteine molecule acts as a precursor for the intracellular synthesis of glutathione (GSH). This increased intracellular GSH concentration augments the endogenous antioxidant capacity of the respiratory epithelium. This molecular pathway provides system-level protection against reactive oxygen species by enhancing the scavenging and neutralization of oxidative stressors within the mucosal lining.

Dosage and Administration Information

The administration route for Pectox lisina is strictly oral, utilizing liquid dosage forms such as syrup, oral solution, or the 2.7 g granules for solution. The dosing structure begins with an initial daily dosage of 2250 mg of Carbocysteine, typically divided into multiple administrations. The objective of this initial phase is to establish a sufficient systemic level. Once a satisfactory response is achieved, the regimen is reduced to a maintenance daily dosage of 1500 mg.

Dosing frequency varies by formulation: the general regimen is often administered three times per day, while the high-dose 2.7 g Carbocysteine Lysine salt preparation is intended for a once-daily schedule. For administration, the solution is measured using the dedicated syringe or cup provided to ensure dose accuracy; the use of household utensils is avoided. The medicine may generally be taken with or without food.

Standard adult dosing applies to older adults, but pediatric dosing is specific to defined age groups and is not recommended for children under two years of age. If a dose is missed, the standard approach is to take it as soon as it is remembered, unless the next dose is due shortly, in which case the missed dose is skipped.

Recent Clinical Evidence

Research Evidence / Overview of studies for Pectox lisina

Evidence for use in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis

Research has examined the use of Pectox lisina (Carbocysteine) over extended periods in adults with stable chronic respiratory conditions like COPD and chronic bronchitis. The evidence base includes several Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. These studies explored outcomes related to systemic or functional imbalance, such as the frequency of acute flare-ups (exacerbations), and patient-reported outcomes describing perceived discomfort and overall health-related quality of life.

Findings describe patterns observed in the studies over follow-up periods that often lasted six to twelve months. Research describes data points measured during the study period related to the number of episodic or acute changes. However, the evidence quality varies across studies, and findings were mixed when assessing the effect on objective measures of lung function, such as how much air a person can exhale in one second (FEV₁). These results apply only to the populations studied.

Evidence for use in Acute Respiratory Episodes

The evidence for using the medicine during conditions associated with acute or disruptive episodes, such as acute bronchitis, is mainly derived from smaller-scale, short-term controlled trials. Research explored short-term symptom changes over periods typically lasting a few weeks. Outcomes studied included patient-reported outcomes describing perceived discomfort related to cough and the difficulty of clearing thick mucus. Studies reported measured changes in short-term changes in the physical characteristics of the respiratory secretions. The evidence is limited in providing context for longer-term management, and sample sizes were modest in many of these trials.

What is Still Uncertain in the Research Landscape

The current evidence highlights several areas where research is ongoing or where data are incomplete. One key uncertainty is the heterogeneity (differences) in the study designs, which may make drawing universal conclusions challenging. The long-term effects are not fully established for use extending beyond one year. Comparative evidence is lacking or evidence quality varies across studies when comparing the compound to all other established therapies. The research structure suggests that studies describe group patterns, and findings related to certain subgroups may be uncertain.

Key Studies & References

Carbocysteine as Adjuvant Therapy in Acute Respiratory Tract Infections in Patients without Underlying Chronic Conditions: Systematic Review and Meta-Analysis

Frequently Asked Questions (FAQ)

Common questions about Pectox lisina (FAQ)

Q: What is the difference between Pectox lisina and a typical cough suppressant?

Pectox lisina is a mucolytic agent that works by thinning mucus to make it easier to clear. Regulatory labels advise against taking it simultaneously with cough-calming medicines. This is because the mucolytic action is understood to rely on the body's natural cough reflex for the clearance of thinned mucus.

Q: What are the official indications for which Pectox lisina is prescribed?

Official product information states that the medicine is indicated as adjunctive therapy for respiratory tract disorders. These are conditions characterized by excessive, thick, or viscous mucus, such as chronic obstructive airways disease (COPD).

Q: How soon after taking Pectox lisina can I expect to notice an effect?

Pharmacokinetic studies indicate that the active substance is rapidly absorbed after oral intake, with maximum concentration in the bloodstream typically reached within two hours of administration. This pharmacokinetic information provides context for the drug's rapid systemic availability.

Q: What is the recommended general duration of Pectox lisina treatment?

The appropriate length of treatment is highly dependent on the individual condition. For chronic conditions, it may be prescribed for long periods. However, the effectiveness of the treatment is subject to periodic review by the prescribing clinician.

Q: Does Pectox lisina help with both chest congestion and throat irritation?

Official information states that the medicine is indicated for disorders characterized by excessive, viscous mucus, which is the mechanism for addressing chest congestion. While the drug is intended to assist in the clearance of mucus, regulatory labels do not specifically mention relief from throat irritation as an indicated benefit.

Q: Are there general suggestions for managing digestive side effects from this medicine?

Some individuals may experience common digestive side effects like diarrhoea or nausea. For diarrhoea, official advice suggests drinking lots of fluids. For nausea, general advice suggests simple meals or taking the medicine after eating. These are general measures described in patient information.

Q: Does Pectox lisina typically cause sleepiness or drowsiness?

Official regulatory labels generally state that the medicine has no or negligible influence on the ability to drive or use machines. This regulatory assessment suggests that Pectox lisina does not commonly cause sleepiness or drowsiness.

Q: Are there official warnings about Pectox lisina affecting the ability to drive or operate machinery?

Regulatory information indicates that this medicine has no or negligible influence on the ability to drive or use machinery. This assessment is based on the known pharmacological profile of the active substance.

Q: What are the signs of a possible serious allergic reaction to Pectox lisina?

Official warnings state that a serious allergic reaction is a rare but possible event. Signs of this may include sudden swelling of the lips, mouth, throat, or tongue, or difficulty breathing. Becoming confused or dizzy can also be a sign of a severe systemic response.

Q: Are there any known or theoretical interactions between Pectox lisina and common pain relievers?

Official regulatory sources advise caution if the medicine is taken with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which include some common pain relievers. This caution relates to an additive risk of gastrointestinal bleeding, especially for patients with a history of ulcers.

Q: Can elderly patients take Pectox lisina without special precautions?

While the standard adult dosage is applied to older adults, regulatory documents specifically recommend general caution in the elderly population. This caution is consistent with regulatory protocol for this age group.

Q: What warnings exist for individuals with severe respiratory conditions taking Pectox lisina?

Official sources advise caution should be exercised for patients with pre-existing severe respiratory failure. Caution is also noted for patients who are generally debilitated, as a precaution related to overall respiratory function.

Q: Is Pectox lisina typically available to purchase over the counter (OTC)?

Regulatory classification varies depending on the specific country or region. In some regions, the medicine is classified as a Pharmaceutical Over-The-Counter (OTC) product, meaning it may be available without a prescription.

Q: Are there clinical studies that examine the anti-inflammatory effects of Pectox lisina’s active component?

Regulatory information focuses on the drug's role as a mucoregulator and its known antioxidant capacity, which is due to increasing the natural glutathione (GSH) synthesis in the respiratory lining. The information does not explicitly make a regulatory anti-inflammatory claim.

Q: Why might mucus appear thinner or more abundant after starting Pectox lisina?

The medicine works by reducing the viscosity (thickness) of the mucus, resulting in thinned secretions. This change in consistency is intended to favor expectoration. Mucus may appear thinner or more abundant because it is easier to clear from the airways.

Q: What is the standard recommended course of action in case of an accidental overdose of Pectox lisina?

Official product information describes that gastrointestinal disturbance (stomach pain, nausea, vomiting) is the most likely symptom of overdose. Official guidance indicates that supportive therapy may be instituted, and gastric lavage may be considered by medical professionals. This information is intended for healthcare providers.

Q: Are there any official warnings regarding the use of Pectox lisina in patients with asthma?

Regulatory warnings indicate that special attention is required for asthmatic patients due to a rare risk of bronchospasm or bronchoconstriction (tightening of the airways). If this occurs, regulatory advice states that treatment should be stopped.

Q: What specific disorders of the mucous secretion is Pectox lisina meant to address?

The medicine is indicated for the treatment of respiratory tract disorders characterized by excessive, viscous mucus. The overall purpose is to manage the challenges associated with the retention of thick airway material.

Q: Is Pectox lisina considered safe for long-term use in chronic lung diseases?

Clinical trials have examined the medicine's use in chronic conditions, with studies often lasting up to 12 months. However, regulatory research overviews state that the long-term effects for use extending beyond one year are not fully established.

Q: What are the potential side effects not listed in the patient leaflet but reported by users?

Official drug safety schemes, such as the Yellow Card Scheme, encourage patients to report any suspected adverse reactions, including those not listed in the patient leaflet. This is how the safety profile is continually monitored and updated using post-marketing data.

Q: Can Pectox lisina be taken if someone is also taking multiple vitamin or mineral supplements?

Official guidance on interactions advises patients to tell their doctor or pharmacist if they are taking herbal remedies or supplements. No formal mandatory restrictions are documented concerning interactions with vitamins or minerals.

Q: Why would Pectox lisina be preferred over a regular carbocisteine formulation?

Official product formulation information indicates that the use of the L-Lysine salt helps optimize the stability and solubility of the active substance. This is particularly beneficial for the liquid oral solution format.

How should Pectox lisina be stored and disposed of?

Storage and Disposal Requirements

The storage and disposal instructions for Pectox lisina (Carbocysteine Lysine) must adhere strictly to the conditions specified in the official regulatory labeling.

Storage Conditions

Requirement	Details
Temperature	No special storage temperature conditions are required before the expiry date.
Child Safety	The medicine must be kept out of the sight and reach of children.
Expiry	Do not use the medicine after the expiry date (CAD) printed on the carton.

Disposal Instructions

Do not dispose of unused or expired Pectox lisina via household waste or wastewater.
All unused product and containers must be taken to the designated pharmaceutical waste collection point (e.g., SIGRE) at the pharmacy.

This method ensures the product is handled as controlled pharmaceutical waste and prevents potential environmental contamination.

Pectox lisina